Skip to main content
Caplight Logo









Athernal Bio

Athernal Bio

Private
CambridgeHealthcare & Life Scienceshttps://athernalbio.com/

Last Round

VC Round

Oct 1, 2025

Total Funding Raised

$12,600

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Athernal Bio is a biotechnology company developing targeted immunotherapies for high-risk clonal haematopoiesis, a blood cancer precursor condition, with the goal of preventing cancer before it starts.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

immunotherapyclonal haematopoiesisCHblood cancer preventionpreclinical biotechnologyAMLacute myeloid leukaemiahaematopoietic stem cellcancer drug discoveryprecision medicinebiotech startuptherapeutic pipelinedrug developmentcancer prevention

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Athernal Bio Comparables

Compare Athernal Bio with similar companies based on industry and business-model similarity.

Athernal Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Novartis
63%
Bristol Myers Squibb
61%
Servier
48%

Athernal Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundOct 1, 2025
AcceleratorMay 30, 2024

Key People

Founding team and executive leadership

Caroline Haegeman

Chief Operating Officer (COO), Founding Team

Founding Team

Athernal Bio Investors

Notable investors and investment history

Athernal Bio investors
InvestorRounds
Accelerate@BabrahamAccelerator
Delin VenturesVC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 1, 2025

    $4.7M round led by Delin Ventures

Recent news

Latest coverage and updates

  • receives_financingSep 9, 2026

    Athernal Bio received financing of $948K in grant on Sep 9th '26.

  • is_developingSep 9, 2026

    Athernal Bio is developing targeted immunotherapies on Sep 9th '26.

Athernal Bio Filings

Explore SEC and related filing metadata, where available.

Athernal Bio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Athernal Bio's valuation, stock price, and market status.

Is Athernal Bio a public or private company?

Athernal Bio is a private company.

What is the current stock price of Athernal Bio?

Athernal Bio is a private company with no public stock price. No recent secondary market data is available.

How much is Athernal Bio worth (valuation)?

Valuation information for Athernal Bio is not publicly available.

Can I buy Athernal Bio stock?

Athernal Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Athernal Bio's last funding round?

Athernal Bio's most recent funding round was Seed on October 1, 2025.

Who are the main investors in Athernal Bio?

Key investors in Athernal Bio include Delin Ventures.

Will Athernal Bio IPO soon?

No public IPO plans have been announced for Athernal Bio.

How can I track Athernal Bio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Athernal Bio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersCambridge
Employee Range4
Year Founded2024
Last FundingOct 1, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?